565 related articles for article (PubMed ID: 11416112)
1. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
[TBL] [Abstract][Full Text] [Related]
2. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
3. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Harbeck N; Kates RE; Schmitt M
J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.
Harbeck N; Kates RE; Schmitt M; Gauger K; Kiechle M; Janicke F; Thomassen C; Look MP; Foekens JA
Clin Breast Cancer; 2004 Dec; 5(5):348-52. PubMed ID: 15585071
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases.
Vénat-Bouvet L; Fermeaux V; Leobon S; Saidi N; Monteil J; Mollard J; Aubard Y; Jammet I; Tubiana-Mathieu N
Anticancer Res; 2014 Mar; 34(3):1213-7. PubMed ID: 24596362
[TBL] [Abstract][Full Text] [Related]
7. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
8. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Foekens JA; Beex LV; Sweep CG
Cancer Res; 2004 Jan; 64(2):659-64. PubMed ID: 14744782
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
Kantelhardt EJ; Vetter M; Schmidt M; Veyret C; Augustin D; Hanf V; Meisner C; Paepke D; Schmitt M; Sweep F; von Minckwitz G; Martin PM; Jaenicke F; Thomssen C; Harbeck N
BMC Cancer; 2011 Apr; 11():140. PubMed ID: 21496284
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Harbeck N; Schmitt M; Kates RE; Kiechle M; Zemzoum I; Jänicke F; Thomssen C
Clin Breast Cancer; 2002 Aug; 3(3):196-200. PubMed ID: 12196277
[TBL] [Abstract][Full Text] [Related]
11. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.
Viala M; Alexandre M; Thezenas S; Lamy PJ; Maran-Gonzalez A; Gutowski M; Colombo PE; Romieu G; Jacot W; Guiu S
Breast Cancer Res Treat; 2017 Oct; 165(3):611-621. PubMed ID: 28685212
[TBL] [Abstract][Full Text] [Related]
13. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer.
Jänicke F; Schmitt M; Pache L; Ulm K; Harbeck N; Höfler H; Graeff H
Breast Cancer Res Treat; 1993; 24(3):195-208. PubMed ID: 8435475
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Horch HH
Mund Kiefer Gesichtschir; 2004 May; 8(3):180-90. PubMed ID: 15138856
[TBL] [Abstract][Full Text] [Related]
15. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
16. High levels of uPA and PAI-1 predict a good response to anthracyclines.
Borstnar S; Sadikov A; Mozina B; Cufer T
Breast Cancer Res Treat; 2010 Jun; 121(3):615-24. PubMed ID: 20039121
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
19. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
Harbeck N; Thomssen C
Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
[TBL] [Abstract][Full Text] [Related]
20. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]